Huatai Bairui Fund Management Co. Ltd. - CSI Shanghai Hong Kong Shenzhen Innovative Drug ETF (SHA:517120)
0.7820
0.00 (0.00%)
At close: Sep 23, 2026
SHA:517120 Holdings Information
SHA:517120 is an equity ETF with a total of 78 individual holdings. The top holdings are WuXi AppTec stock at 15.12%, BeOne Medicines AG at 10.56%, Jiangsu Hengrui Pharmaceuticals Co.,Ltd at 10.00%, WuXi Biologics at 6.90%, and Innovent Biologics at 6.76%.
Total Holdings
78
Top 10 Percentage
61.79%
Asset Class
Equity
ETF Category
Health Care
Assets
n/a
PE Ratio
n/a
Breakdown by Sector
Top 25 Holdings
| No. | Symbol | Name | % Weight |
|---|---|---|---|
| 1 | SHA: 603259 | WuXi AppTec Co., Ltd. | 11.41% |
| 2 | SHA: 600276 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 10.00% |
| 3 | HKG: 6160 | BeOne Medicines AG | 9.24% |
| 4 | HKG: 2269 | WuXi Biologics (Cayman) Inc. | 6.90% |
| 5 | HKG: 1801 | Innovent Biologics, Inc. | 6.76% |
| 6 | n/a | Cash | 4.83% |
| 7 | HKG: 2359 | WuXi AppTec Co., Ltd. | 3.71% |
| 8 | HKG: 9926 | Akeso, Inc. | 3.47% |
| 9 | HKG: 3692 | Hansoh Pharmaceutical Group Company Limited | 2.76% |
| 10 | HKG: 1093 | CSPC Pharmaceutical Group Limited | 2.72% |
| 11 | HKG: 1177 | Sino Biopharmaceutical Limited | 2.38% |
| 12 | SHE: 002422 | Sichuan Kelun Pharmaceutical Co., Ltd. | 2.34% |
| 13 | SHE: 002821 | Asymchem Laboratories (Tianjin) Co., Ltd. | 1.73% |
| 14 | HKG: 1530 | 3SBio Inc. | 1.65% |
| 15 | SHE: 300759 | Pharmaron Beijing Co., Ltd. | 1.63% |
| 16 | HKG: 6990 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 1.61% |
| 17 | SHA: 688578 | Shanghai Allist Pharmaceuticals Co., Ltd. | 1.60% |
| 18 | SHA: 600196 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 1.55% |
| 19 | HKG: 2268 | WuXi XDC Cayman Inc. | 1.44% |
| 20 | SHA: 688331 | RemeGen Co., Ltd. | 1.38% |
| 21 | SHE: 300347 | Hangzhou Tigermed Consulting Co., Ltd | 1.37% |
| 22 | SHE: 000963 | Huadong Medicine Co., Ltd | 1.33% |
| 23 | SHA: 688235 | BeOne Medicines AG | 1.32% |
| 24 | HKG: 2228 | XtalPi Holdings Limited | 1.30% |
| 25 | SHA: 688266 | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | 1.27% |
As of Jun 30, 2026